We are live on ! Find out more
CALA

Calithera Biosciences, Inc

Delisted

CALA was delisted on the 1st of February, 2023.

112 hedge funds and large institutions have $204M invested in Calithera Biosciences, Inc in 2017 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 38 increasing their positions, 23 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 15

65% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 23

23% more funds holding

Funds holding: 91112 (+21)

10% less call options, than puts

Call options by funds: $768K | Put options by funds: $855K

50% less capital invested

Capital invested by funds: $406M → $204M (-$202M)

Holders
112
Holders Change
+21
Holders Change %
+23.08%
% of All Funds
2.54%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
36
Increased
38
Reduced
23
Closed
15
Calls
$768K
Puts
$855K
Net Calls
-$87K
Net Calls Change
+$531K
Name Holding Trade Value Shares
Change
Change in
Stake
Jacobs Levy Equity Management
76
Jacobs Levy Equity Management
New Jersey
$155K
Principal Financial Group
77
Principal Financial Group
Iowa
$148K +$227K +886 New
RJFSA
78
Raymond James Financial Services Advisors
Florida
$142K
State Board of Administration of Florida Retirement System
79
State Board of Administration of Florida Retirement System
Florida
$127K
IWM
80
IHT Wealth Management
Illinois
$125K +$191K +745 New
California Public Employees Retirement System
81
California Public Employees Retirement System
California
$118K -$379K -1,481 -68%
VOYA Investment Management
82
VOYA Investment Management
Georgia
$118K
Citigroup
83
Citigroup
New York
$111K -$571K -2,231 -77%
Jane Street
84
Jane Street
New York
$103K +$159K +619 New
FAAS
85
First Allied Advisory Services
California
$94K +$143K +558 New
NIT
86
NumerixS Investment Technologies
British Columbia, Canada
$93K +$14.1K +55 +11%
UBS AM
87
UBS AM
Illinois
$91.8K +$141K +550 New
Two Sigma Advisers
88
Two Sigma Advisers
New York
$86K +$132K +515 New
FAM
89
Fred Alger Management
New York
$84K
Legal & General Group
90
Legal & General Group
United Kingdom
$64K -$5.12K -20 -5%
BNP Paribas Financial Markets
91
BNP Paribas Financial Markets
France
$59.8K +$49.4K +193 +117%
JP Morgan Chase
92
JP Morgan Chase
New York
$55K +$84.5K +330 New
Group One Trading
93
Group One Trading
Illinois
$54K -$250K -977 -75%
Parallax Volatility Advisers
94
Parallax Volatility Advisers
California
$39K +$59.7K +233 New
CG
95
Cutler Group
California
$32K -$109K -426 -69%
SO
96
STRS Ohio
Ohio
$30K
Canada Life
97
Canada Life
Manitoba, Canada
$27K +$42.3K +165 New
AIP
98
Ameritas Investment Partners
Nebraska
$22K
TRCT
99
Tower Research Capital (TRC)
New York
$19K +$26.6K +104 +1,156%
Pacer Advisors
100
Pacer Advisors
Pennsylvania
$12K +$18.9K +74 New

CALA Hedge Fund Activity: Q4 2017 in Review

112 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q4 2017, worth a combined $204M — down 50% from $406M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new CALA positions and 15 closed out — a net gain of 21 holders — while 38 added to existing stakes and 23 trimmed.

The largest buyer was Millennium Management, adding an estimated $12.3M. The largest seller was Adage Capital Partners, cutting an estimated $24.9M.

  • 112 institutional investors held Calithera Biosciences, Inc (CALA) as of Q4 2017, up from 91 in Q3 2017.
  • Funds reported $204M of Calithera Biosciences, Inc stock for Q4 2017, down 50% quarter-over-quarter.
  • 36 funds opened new Calithera Biosciences, Inc positions in Q4 2017 and 15 closed out, a net change of +21 holders.
  • The largest Calithera Biosciences, Inc buyer in Q4 2017 was Millennium Management, an estimated $12.3M added.
  • The largest Calithera Biosciences, Inc seller in Q4 2017 was Adage Capital Partners, an estimated $24.9M sold.

Based on aggregated 13F filings for Q4 2017.